Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials ; volume:8 ; number:1 ; day:12 ; month:5 ; year:2016 ; pages:1-13 ; date:12.2016
Alzheimer's research & therapy ; 8, Heft 1 (12.5.2016), 1-13, 12.2016
- Beteiligte Personen und Organisationen
-
Vandenberghe, Rik
Rinne, Juha O.
Boada, Mercè
Katayama, Sadao
Scheltens, Philip
Vellas, Bruno
Tuchman, Michael
Gass, Achim
Fiebach, Jochen B.
Hill, Derek
Lobello, Kasia
Li, David
McRae, Tom
Lucas, Prisca
Evans, Iona
Booth, Kevin
Luscan, Gerald
Wyman, Bradley T.
Hua, Lisa
Yang, Lingfeng
Brashear, H. Robert
Black, Ronald S.
SpringerLink (Online service)
- DOI
-
10.1186/s13195-016-0189-7
- URN
-
urn:nbn:de:1111-201605183583
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Vandenberghe, Rik
- Rinne, Juha O.
- Boada, Mercè
- Katayama, Sadao
- Scheltens, Philip
- Vellas, Bruno
- Tuchman, Michael
- Gass, Achim
- Fiebach, Jochen B.
- Hill, Derek
- Lobello, Kasia
- Li, David
- McRae, Tom
- Lucas, Prisca
- Evans, Iona
- Booth, Kevin
- Luscan, Gerald
- Wyman, Bradley T.
- Hua, Lisa
- Yang, Lingfeng
- Brashear, H. Robert
- Black, Ronald S.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future
The “rights” of precision drug development for Alzheimer’s disease
Eyes-closed task-free electroencephalography in clinical trials for Alzheimer’s disease: an emerging method based upon brain dynamics
Clinical Features of Patients with Alzheimer’s Disease and a History of Traumatic Brain Injury
Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease
The plasma peptides of Alzheimer’s disease
Reproducibility of EEG functional connectivity in Alzheimer’s disease
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease
Declining functional connectivity and changing hub locations in Alzheimer’s disease: an EEG study
Sensitive and reproducible MEG resting-state metrics of functional connectivity in Alzheimer’s disease
A multiscale brain network model links Alzheimer’s disease-mediated neuronal hyperactivity to large-scale oscillatory slowing
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future
The “rights” of precision drug development for Alzheimer’s disease
Eyes-closed task-free electroencephalography in clinical trials for Alzheimer’s disease: an emerging method based upon brain dynamics
Clinical Features of Patients with Alzheimer’s Disease and a History of Traumatic Brain Injury
Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease
The plasma peptides of Alzheimer’s disease
Reproducibility of EEG functional connectivity in Alzheimer’s disease
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease
Declining functional connectivity and changing hub locations in Alzheimer’s disease: an EEG study
Sensitive and reproducible MEG resting-state metrics of functional connectivity in Alzheimer’s disease
A multiscale brain network model links Alzheimer’s disease-mediated neuronal hyperactivity to large-scale oscillatory slowing
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future
The “rights” of precision drug development for Alzheimer’s disease
Eyes-closed task-free electroencephalography in clinical trials for Alzheimer’s disease: an emerging method based upon brain dynamics
Clinical Features of Patients with Alzheimer’s Disease and a History of Traumatic Brain Injury
Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease
The plasma peptides of Alzheimer’s disease
Reproducibility of EEG functional connectivity in Alzheimer’s disease
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease
Declining functional connectivity and changing hub locations in Alzheimer’s disease: an EEG study
Sensitive and reproducible MEG resting-state metrics of functional connectivity in Alzheimer’s disease